GelStat Corporation Signs Binding Definitive Agreement to Acquire
Mastix Medica, LLC
PALM CITY, FL--(Marketwired
- June 05, 2014) - GelStat Corporation (PINKSHEETS: GSAC), a company engaged in the
research, development, marketing and branding of innovative
Over-the-Counter (OTC) consumer healthcare products, is pleased to
announce it signed a definitive agreement to acquire Mastix Medica,
LLC. The final closing of the acquisition is expected to take
place on or before July 7, 2014. The acquisition is a significant
milestone for GelStat and is expected to add over $500,000 in
revenue in the third quarter ending September 30, 2014.
Larry Gershman, GelStat's Chairman and CEO, said, "The
acquisition of Mastix Medica adds another dimension to GelStat that
complements our present experience in product innovation and
marketing. The vertical integration also enhances our
profitability of recently introduced dietary supplement Chews 2
Loseā¢ appetite suppressant gum. More importantly, the
acquisition brings to GelStat a key asset and foothold in the
explosive high CBD/low THC industrial hemp and medical marijuana
market. We are also excited to be adding Bob Estey to our
management team as he brings a wealth of financial management
experience as well as manufacturing capabilities to the GelStat
team."
Robert ("Bob") Estey said, "I am delighted to become part of the
GelStat team. The combination of their leading scientific advisors
and marketing team with our unique, proprietary manufacturing
processes makes us a vertically integrated one-stop shop for
product innovation from concept through manufacturing, clinical
validation and marketing. Furthermore, Larry's deep knowledge of
the CBD market and vast industry connections worldwide have already
opened up significant opportunities in this rapidly growing
market."
Make sure you are first to receive timely information on GelStat
Corporation when it hits the newswire. Sign up for GelStat's email
news alert system today at:
http://ir.stockpr.com/gelstat/request-information
ABOUT MASTIX MEDICA
Mastix Medica was founded in 2009 to develop niche healthcare
products in underutilized, emerging dosage forms like tableted
chewing gum, chewable tablets and lozenges. Using an in-house
product development team, Mastix Medica develops custom tablet
formulations that incorporate dietary supplements for companies
competing in a variety of markets, including energy, immune
support, weight loss, pain relief and dental health. Mastix
Medica has developed and manufactured products for a wide range of
customers including companies with national brands like AirborneĀ®
and Jakks Pacific, Bhang Chocolates, Medical Marijuana Incorporated
"MJNA", and the U.S. Military's ration kits and companies with
unique custom formulations in smaller brands.
Mastix Medica is one of very few companies in the world that has
the ability to make tableted chewing gum products. It has also
developed a proprietary direct compression tableting process that
is excellent for delivering supplements and active
ingredients. A patent application has been filed for this
unique gum making process.
Mastix Medica has formulated a chewing gum product with
industrial hemp oil which is rich in cannabidiol (CBD), and is also
able to make a lozenge or a chewable tablet with hemp
oil. Mastix Medica is the only chewing gum manufacturer that
can incorporate an ingredient like hemp oil into a piece of chewing
gum using its proprietary, patent pending manufacturing process
that is very specialized to accommodate a unique active like hemp
oil.
Mastix Medica only uses industrial hemp oil that is rich in
cannabidiol (CBD) and non-psychoactive (very low THC). CBD has seen
increased awareness recently due to its clinically proven ability
to treat disorders such as arthritis and migraines while showing
improved general health and wellness. (This statement has not
been evaluated by the Food and Drug Administration).
For more information on Mastix Medica visit:
http://mastixmedica.com
ABOUT GELSTAT CORPORATION
GelStat Corporation is a publicly traded company trading under
the symbol ("GSAC") that is engaged in research, development,
marketing and branding of innovative over-the-counter (OTC)
consumer healthcare products addressing very large markets. The
Company's initial products include GelStat Migraine, GelStat Sleep,
Chews 2 Lose and All Natural Speed. The Company also has a suite of
additional healthcare products in various stages of development
that address large consumer markets.
Decision Resources, one of the world's leading research and
advisory firms for pharmaceutical and healthcare issues, expects
the market for migraine therapies to grow from $3.3 billion in 2011
to $5.8 billion in 2021 in the United States, France, Germany,
Italy, Spain, the United Kingdom and Japan.
The total over-the-counter market for sleep aids alone reached
$604 million in 2008, an increase of 9 percent over 2007, according
to Packaged Facts, a division of Rockville, Md.-based Market
Research Group.
According to Marketdata Enterprises, Inc., a leading independent
market research publisher of "off-the-shelf" studies about service
industries since 1979, an estimated 75 million dieters spent $2.7
billion in 2010 on diet pills and meal replacements.
According an article published by Companies and Markets.com, the
US energy drinks market is estimated to have increased by 60% over
the past four years, hitting an estimated value of $12.5 billion in
2012. The industry is expected to continue this growth path, by
rising to a valuation of $21.5 billion by 2017.
For more information, visit www.gelstat.com.
Safe Harbor Statement
This press release and the shareholder letter contains
forward-looking statements including pursuing strategic
relationships, building and leveraging a direct-to consumer
platform to launch new products, acquiring or licensing the rights
to products with proven science, growing organically and
achieving each of the goals mentioned
above. Forward-looking statements can be identified by words
such as "anticipates," "intends," "plans," "seeks," "believes,"
"estimates," "expects" and similar references to future
periods.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. We caution you therefore against
relying on any of these forward-looking statements. They are
neither statements of historical fact nor guarantees or assurances
of future performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements include the failure of our products to be accepted,
failure to obtain partners to market and distribute our products,
unanticipated delays in launching website or failure of the website
to generate revenues, our inability to find a target to acquire on
mutually acceptable terms, and the inability to get our reports
prepared and filed timely as a result of unforeseen audit
issues.
Any forward-looking statement made by us in this press release
speaks only as of the date on which it is made. Factors or events
that could cause our actual results to differ may emerge from time
to time, and it is not possible for us to predict all of them. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by law.
FOR ADDITIONAL INFORMATION CONTACT:Gerald KieftCFOGelStat
Corporation772-283-0020
GelStat (PK) (USOTC:GSAC)
Historical Stock Chart
From Nov 2024 to Dec 2024
GelStat (PK) (USOTC:GSAC)
Historical Stock Chart
From Dec 2023 to Dec 2024
See More Message Board Posts
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.